<DOC>
<DOCNO>EP-0654994</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of cineol or menthol for the treament of asthma
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P4300	A61K31085	A61P900	A61K948	A61K31095	A61P3700	A61K908	A61K3112	A61K31045	A61K3110	A61K3157	A61K908	A61P2900	A61P306	A61K31352	A61P300	A61P1302	A61P3708	A61K3135	A61K3105	A61P1500	A61K3112	C07D31100	A61P1300	A61P3700	A61P1100	A61K3157	A61K31075	A61K31045	A61K3135	A61P4300	A61P100	A61K31573	A61P1100	A61P2900	C07D31100	A61P900	A61K948	A61K31352	A61P1500	A61P116	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	A61K	A61K	A61P	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61K	A61P	A61P	A61P	A61K	A61K	A61P	A61K	C07D	A61P	A61P	A61P	A61K	A61K	A61K	A61K	A61P	A61P	A61K	A61P	A61P	C07D	A61P	A61K	A61K	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P43	A61K31	A61P9	A61K9	A61K31	A61P37	A61K9	A61K31	A61K31	A61K31	A61K31	A61K9	A61P29	A61P3	A61K31	A61P3	A61P13	A61P37	A61K31	A61K31	A61P15	A61K31	C07D311	A61P13	A61P37	A61P11	A61K31	A61K31	A61K31	A61K31	A61P43	A61P1	A61K31	A61P11	A61P29	C07D311	A61P9	A61K9	A61K31	A61P15	A61P1	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Saturated mono- or bicyclic terpene alcohols, ethers, ketones or thiols are used to suppress the release of arachidonic acid from  the phospholipid stores in human cells.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
JUERGENS UWE R
</APPLICANT-NAME>
<APPLICANT-NAME>
JUERGENS, UWE R.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
JUERGENS UWE R
</INVENTOR-NAME>
<INVENTOR-NAME>
JUERGENS, UWE R.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of 1,8-oxido-p-menthane or menthane-3-ol for production of drugs in the
form of capsules resistant to gastric juice, infusion solutions or as solutions

for intramuscular injection for treatment of bronchial asthma.
Use according to claim 1 for the reduction of systemically active
corticosteroids.
Use according to claim 1 or 2 for monotherapy in mild or slight bronchial
asthma as well as for treatment of children with asthma.
Use for prophylaxis according to one of the claims 1 to 3.
Use according to claims 1, 2 or 4 in combination with systemically active
drugs, especially immunosuppressives or corticosteroids.
Use according to one of the claims 1 to 5 characterized by a total daily intake
amount of 1,8-oxido-p-menthane or menthane-3-ol in the range from 100 mg

to 900 mg.
Use of 1,8-oxido-p-menthane for the purposes of claim 1 in a total daily
intake amount between 200 mg and 900 mg, preferably 600 mg.
Use of methane-3-ol for the purposes of claim 1 in a total daily intake
amount between 100 mg and 450 mg.
Use according to one of the claims 1 to 8 characterized by a dose unit for
oral therapy in the form of capsules resistant to gastric juice of 100 mg.
</CLAIMS>
</TEXT>
</DOC>
